Myasthenia Gravis

Using US claims data, the authors evaluated oral glucocorticoid (GC) use at 5 time points during their retrospective analysis: 3 months before starting efgartigimod and 3, 6, 9, and 12 months after starting efgartigimod.

The humanized IgG4 monoclonal antibody was first approved for myasthenia gravis in the US in 2023, with approvals in Japan and the European Union following later that year and 2025, respectively.

Despite nurses often being the first health care workers many patients encounter, they frequently lack adequate tools to optimally evaluate their patients’ conditions, as in the case with myasthenia gravis and being able to predict patients at risk of myasthenic crisis.

Among patients who have myasthenia gravis, even low disease activity can impact their quality of life (QOL) via motor fatiguability.

Fear of progression is common among patients living with chronic diseases, but the degree to which it interferes with patient outcomes, including treatment adherence, deserves further investigation, study authors note.

The primary end point in PREVAIL is Myasthenia Gravis-Activities of Daily Living total score improvement from baseline, and the secondary end points are Quantitative Myasthenia Gravis total score and Myasthenia Gravis Composite total score.

Miriam Freimer, MD, clinical professor of neurology at The Ohio State University Wexner Medical Center, reflects on how findings from the RAISE-XT trial potentially translate to real-world practice and looks to the future of treatment for the autoimmune neuromuscular disorder.

Three patient outcomes were measured in this new study: time to onset of ocular-related myasthenia gravis, Activities of Daily Living response, and Minimal Symptom Expression.

Mirima Freimer, MD, delves into potential reasons behind the longer-term efficacy of zilucoplan and also speaks to the treatment’s safety profile.

Nipocalimab's FDA approval revolutionizes generalized myasthenia gravis treatment, offering rapid symptom relief and improved patient outcomes across diverse populations.

In myasthenia gravis, complement plays a big role in what happens to the muscle end of the neuromuscular junction, explains Miriam Freimer, MD, an author on 5 abstracts presented at the recent 15th MGFA International Conference on Myasthenia and Related Disorders.

In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.

Telitacicept is a dual-targeting agent that attaches to and blocks the effects of 2 key signaling proteins, B-lymphocyte stimulator and a proliferation-inducing ligand, to treat the B-cell–mediated autoimmune disease, generalized myasthenia gravis.

Zilucoplan (Zilbrysq; UCB) is a once-daily subcutaneous C5 complement inhibitor that has demonstrated long-term treatment benefits in patients who have acetylcholine receptor antibody–positive generalized myasthenia gravis (gMG).

Combining FRAX and MG-ADL assessments enhances fracture risk prediction in patients with myasthenia gravis (MG), guiding targeted interventions for better outcomes.

New research reveals light sensitivity significantly impacts quality of life in myasthenia gravis patients, highlighting the need for targeted treatment strategies.

The approval marks the second international approval for rozanolixizumab (Rystiggo; UCB Pharma) for generalized myasthenia gravis (gMG), behind the February EU approval of 2 self-administration approvals for the neonatal Fc receptor monoclonal antibody: an infusion pump and manual push with a syringe.

Nipocalimab (Imaavy; Johnson & Johnson), an FcRn-blocking monoclonal antibody, was approved for patients 12 years and older with generalized myasthenia gravis based on data from the ongoing Vivacity-MG3 study.

Research presented at the recent annual meeting of the Academy of Managed Care Pharmacy highlights outcomes among patients who have anti-acetylcholine receptor antibody-positive myasthenia gravis that include reduced exacerbations and need for immunoglobulin.